In the wake of a $1 billion cost-cutting scheme unveiled in March, Biogen’s head count is dropping in Massachusetts. Still, the company is keeping mum on the exact number of staffers let go in the aftermath of its ill-fated Alzheimer’s disease drug launch.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,